This MedLibrary.org supplementary page on Terfenadine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Terfenadine
|
|
| Systematic (IUPAC) name | |
| 4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]- 1-(4-tert-butylphenyl)-butan-1-ol |
|
| Identifiers | |
| CAS number | |
| ATC code | R06 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C32H41NO2 |
| Mol. mass | 471.673 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 70% |
| Metabolism | ? |
| Half life | 3.5 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was marketed under various brand names including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia. It was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Terfenadine is a prodrug, generally completely metabolised to the active form fexofenadine by the intestinal cytochrome P450 CYP3A4 isoform. Due to this presystemic gut wall metabolism terfenadine normally is not measurable in the plasma. Terfenadine itself, however, has a cardiotoxic effect in higher doses while its metabolites have not such effect. Toxicity is possible after years of continued use with no previous problems as a result of an interaction with other medications such as erythromycin, or foods like grapefruit. The addition of or dosage change in these CYP3A4 inhibitors makes it harder for the body to metabolize and remove the drug. Terfenadine appears in larger concentrations in plasma leading to toxic effects on the heart's rhythm and electrical conduction like ventricular tachycardia and torsades de pointes.
In early 1997, the U.S. FDA recommended that the terfenadine-containing drugs be removed from the market and that physicians consider alternative medications for their patients. Seldane was formally removed from the U.S. market in late 1997 after the approval of Allegra, a drug by the same maker as Seldane that was not found to cause the potentially fatal heart condition.[1] Terfenadine-containing drugs were subsequently removed from the Canadian market in 1999,[2] though they remain available in the UK by prescription only.
References
- ^ Fda Approves Allegra-D, Manufacturer To Withdraw Seldane From Marketplace
- ^ Status of Terfenadine-Containing Drugs in Canada
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
terfenadine is no longer available in the uk
Wikipedia content modification information:
- This page was last modified on 15 September 2008, at 21:02.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Terfenadine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.